Hyperpigmentation Explained: When Uneven Skin Tone Is a Medical Signal, Not Just a Skin Concern

Understanding the medical science, lived symptoms and evidence-based treatments — explained by a doctor.

Written by Dr Rinku Ratti MBBS (London) BSc (Hons) DRCOG DFFP MRCGP
Level 7 Masters in Aesthetics
Private GP, Cosmetic Doctor & Women’s Health Specialist
Instagram: @drrinkuofficial | @thedoctorspractice

Introduction

In our aesthetic clinic in Edgbaston, Birmingham, hyperpigmentation is one of the most frequently discussed concerns. Patients often describe it simply as “uneven skin tone” or “dark patches that won’t fade”.

But clinically, pigmentation is not always just cosmetic.

Sometimes it reflects post-inflammatory change following acne. Sometimes it signals hormonal shifts, metabolic changes or chronic ultraviolet exposure. Occasionally, it can indicate an underlying medical condition that requires investigation rather than exfoliation.

Hyperpigmentation occurs when melanocytes — the pigment-producing cells in the epidermis — increase melanin production or deposit pigment unevenly within the skin. The visible result is darker patches, but beneath the surface lies a complex interaction between inflammation, hormones and cellular signalling.

Understanding the biology determines whether treatment should focus on correction, regulation or investigation.

The Science Behind Pigmentation

Melanin is produced by melanocytes within the basal layer of the epidermis. Its primary role is photoprotection.

When the skin is exposed to ultraviolet radiation, inflammatory mediators stimulate melanogenesis. Enzymes such as tyrosinase drive melanin synthesis, which is then transferred to keratinocytes.

Research published in dermatological journals such as the Journal of Investigative Dermatology describes how chronic UV exposure increases melanocyte activity and alters melanosome distribution. Inflammatory signals — including cytokines released after acne lesions — can also upregulate melanin production.

Pigmentation is therefore both protective and reactive.

Biological Mechanisms Beneath Dark Patches

Hyperpigmentation develops through several mechanisms:

• Increased melanin production
• Abnormal melanin distribution
• Dermal melanin deposition following inflammation
• Hormonal stimulation of melanocytes

Post-inflammatory hyperpigmentation (PIH) follows injury or acne. Melasma, by contrast, is strongly influenced by hormonal signalling and ultraviolet exposure. In both conditions, melanocyte activity becomes dysregulated.

Evidence suggests that oestrogen and progesterone can influence melanocyte stimulation, which partly explains why melasma is common during pregnancy or with hormonal contraception.

Pigmentation is not random. It follows biological pathways.

When Pigmentation Signals Something Deeper

In clinic, uneven skin tone occasionally reveals systemic patterns.

For example:

• Acanthosis nigricans may indicate insulin resistance.
• Diffuse pigmentation changes may accompany endocrine disorders.
• Chronic inflammatory acne can leave persistent post-inflammatory marks.

This is why hyperpigmentation assessment should include medical history, hormonal context and metabolic evaluation where appropriate.

It is not always simply a skincare issue.

Patients struggling with acne-related pigmentation may benefit from understanding the inflammatory basis of breakouts, as explored in our discussion of adult acne and hormonal sensitivity.

Lived Patterns in Women

Hyperpigmentation frequently intensifies during:

• Pregnancy
• Perimenopause
• Periods of high stress
• Following inflammatory skin episodes

As discussed in our guide to menopause-related skin changes, fluctuating oestrogen levels influence collagen density and melanocyte behaviour.

Stress physiology also plays a role. Cortisol can exacerbate inflammatory pathways, indirectly influencing pigment production.

Skin reflects endocrine balance.

What Current Research Indicates

Reviews in dermatology literature indicate that melasma involves both epidermal and dermal pigment deposition, with vascular and inflammatory components contributing to persistence.

Research suggests that strict photoprotection remains foundational. Without UV control, treatment outcomes are limited.

Importantly, over-aggressive resurfacing can worsen pigmentation in darker skin types. Inflammatory insult can amplify melanocyte activity.

Treatment must therefore be calibrated and medically supervised.

Myths About Hyperpigmentation

One misconception is that pigmentation is purely cosmetic.

In some cases, it is a dermatological signpost to deeper metabolic or hormonal shifts.

Another myth is that stronger peels or lasers automatically produce better results.

Excessive inflammation may worsen pigment irregularity.

Finally, many believe pigmentation will fade without intervention. While superficial pigment may lighten, dermal deposition can persist for years.

Restraint and strategy outperform intensity.

Evidence-Based Treatment Approaches

Management depends on the underlying mechanism.

Options may include:

• Topical tyrosinase inhibitors
• Retinoids to normalise keratinocyte turnover
• Carefully selectedchemical peels
• Targetedmicroneedling in appropriate cases
• Regenerative support as outlined in our overview ofadvanced hyperpigmentation treatments

In some patients, metabolic or hormonal review may be warranted alongside aesthetic therapy.

The objective is pigment regulation, not simply surface lightening.

Lifestyle, Sunlight and Prevention

Photoprotection is non-negotiable.

Broad-spectrum sunscreen, protective clothing and behavioural sun avoidance remain central. UV radiation continues to stimulate melanogenesis even on overcast days.

Dietary antioxidants and anti-inflammatory lifestyle measures may support overall skin resilience, though evidence varies in strength.

Pigmentation control is cumulative. So is prevention.

Assessment at The Doctor’s Practice

At The Doctor’s Practice — a private GP-led clinic in Edgbaston, Birmingham — hyperpigmentation assessment begins with clinical differentiation.

We evaluate:

• Distribution pattern
• Depth of pigment
• Hormonal history
• Inflammatory triggers
• Metabolic indicators where appropriate

Our approach integrates medical insight with aesthetic precision. The aim is clarity — identifying whether pigment is reactive, hormonal or systemic before designing treatment.

Uneven skin tone deserves medical interpretation.

Frequently Asked Questions

Is hyperpigmentation always cosmetic?
No. In some cases, it reflects hormonal, inflammatory or metabolic processes.

Can stress worsen pigmentation?
Stress may exacerbate inflammatory signalling, which can indirectly influence melanocyte activity.

Are pigmentation treatments safe for all skin types?
Treatment must be tailored carefully, particularly in darker skin tones where inflammation can worsen pigment deposition.

Is hyperpigmentation common in Birmingham clinics?
Yes. We frequently assess pigmentation concerns at our clinic in Edgbaston, Birmingham.

Will pigmentation return after treatment?
It may recur if hormonal or UV triggers persist. Maintenance and photoprotection are essential.

A Personal Note

Hyperpigmentation can feel subtle yet deeply personal.

It changes how light reflects on the face. It alters confidence quietly.

But skin is dynamic. With correct assessment and measured intervention, improvement is achievable.

The key is recognising when pigmentation is merely cosmetic — and when it is biological.

Book an Appointment with Dr Rinku

The Doctors Practice
7 Chad Square, Hawthorne Road
Edgbaston, Birmingham B15 3TQ
Website: https://www.thedoctorspractice.co.uk
Book: https://thedoctorspractice.co.uk/book-an-appointment/
Google Maps: https://share.google.com/X4VOVkY3Vz5Fgfj1C
Phone: 0121 661 2366
WhatsApp: +447388623527
Instagram: @thedoctorspractice | @drbikofficial | @drrinkuofficial

References

Grimes PE. Melasma. J Am Acad Dermatol. 1995;33(3):S56–S59.

Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31(4):461–465. https://doi.org/10.1111/pcmr.12685

Handog EB, et al. Acanthosis nigricans: clinical and etiologic considerations. Dermatol Clin. 2007;25(4):453–460.